Another factual information on the “Peanut Allergy Vaccine Market” has as of late added by CMI to its storehouse. This research report offers an inside and out examination of various perspectives, for example, market patterns, pieces of the overall industry, drivers, restrictions, opportunities. It gives an investigative view to settle on further choices in organizations. It covers comprehensive instructive information of various key players working over the globe.
Get FREE Sample Report With Latest Covid19 Analysis @ https://www.coherentmarketinsights.com/insight/request-sample/121
An allergy is a medical condition caused by hypersensitivity of the immune system to some external stimuli. Allergies can lead to anaphylaxis, which is a medical condition that causes irritation of skin, shortness of breath, swelling of throat, and in some cases, death. Generally, allergies are caused by various pollen grains or certain foods such as peanut.
Food allergy is one of the major forms of allergies and are caused by eggs, cow’s milk, shellfish, peanuts, etc. The peanut allergy is typically observed in children and thus, peanut allergy market has gained significant traction in the recent past. The peanut allergy vaccine is administered to patients who are detected with probability of peanut allergy, in order to prevent its incidence in the near future. According to a report published by National Centre for Biotechnology Information, allergy to peanuts as well as tree nuts (TNs) is the principal reason for fatal allergic reactions in the U.S., and the occurrences appear to be rising. In this 11 year follow up research, over 1% (around 3 million) people reported peanut or tree nut allergies and the condition has been on the rise, mainly amongst children. According to a report by Food Allergy Research and Education (FARE), peanuts caused the most number of allergies in the U.S., among all food allergens. Hence, peanut allergy vaccine market has a major potential for growth in this region during the forecast period (2018–2026).
Purchase This Premium Report With Discounted Rate: https://www.coherentmarketinsights.com/insight/buy-now/121
Peanut Allergy Vaccine Market Taxonomy
On the basis of end user, the global peanut allergy vaccines market is classified into:
Rising government initiatives to increase awareness and frequent product approvals are expected to propel the global peanut allergy vaccine market growth over the forecast period. Furthermore, increasing prevalence of peanut allergy is expected to drive growth of the global peanut allergy vaccine market during the forecast period. According to American Academy of Allergy Asthma & Immunology, 30.4% of the children with food allergies suffered from multiple allergy attacks. Peanut allergy is such an epidemic condition in the U.S. that the federal Food Allergen Labeling and Consumer Protection Act (FALCPA) mandated that all packaged food sold in the U.S. that include peanuts as an ingredient have to prominently display the word ‘Peanut’ on the label.
For now, the only solution to peanut allergy is restraining a patient from having peanuts or products containing peanuts. However, vaccine is capable of curing the ailment from very young age. According to a research published by Asia Pacific Association of Allergy, Asthma and Clinical Immunology, the prevalence of food allergy (or peanut allergy) in Asia is low as compared to the West. Abundant use of peanuts in local cuisines in Asia Pacific is a major factor attributed to low incidence of peanut allergy in the region. As can be inferred from the report, the peanut allergy vaccine market is expected to grow at a considerable rate in the western part of the globe as compared to the eastern part.
Key companies operating in the global peanut allergy vaccine market are Allergy Therapeutics, Zicam, Aravax, Immunomic Therapeutic, Inc., Astellas, and Aimmune.
Major market players are involved in different business strategies such as research and development, in order to develop effective vaccine for peanut allergy. For instance, in February 2019, Aravax, an Australia-based biotechnology company, presented positive Phase I data for clinical trial, evaluating safety and tolerability of a novel vaccine ‘PVX108’ at 2019 American Academy of Allergy, Asthma & Immunology (AAAAI). This is an intradermal peanut allergy immunotherapy vaccine.
Major market players are involved in different business strategies such as gaining approval from regulatory authorities, in order to develop effective vaccine for peanut allergy. For instance, in March 2019, Aimmue Therapeutics, Inc., a biopharmaceutical company, received Biologics License Application (BLA) for AR101 from the U.S. Food and Drug Administration (FDA) for review. AR101 is indicated for peanut allergy.
Major market players are involved in different business strategies such as partnership and collaboration, in order to develop effective vaccine for peanut allergy. For instance, Sementis, an Australia-based biotechnology company, collaborated with Ensi Pharama, a U.K.-based company, development and evaluation of peanut allergy vaccine.
Request Here For PDF Brochure With Latest Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/121
Table of Content
Global Peanut Allergy Vaccine Market Research Report
Section 1: Global Peanut Allergy Vaccine Industry Overview
Section 2: Global Economic Impact on Peanut Allergy Vaccine Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Peanut Allergy Vaccine Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy, and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Peanut Allergy Vaccine Market Forecast
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027